deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00608972

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic Breast Cancer
Interventions Bevacizumab Carboplatin Doxil
Updated 8 times since 2017 Last updated: Feb 3, 2023 Started: May 16, 2008 Primary completion: Jul 12, 2015 Completion: Sep 25, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00608972, this PHASE2 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Mar 2023 · 26 months · monthly snapshotCompleted~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Mar 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Mar 2023 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Rutgers Cancer Institute of New Jersey
  • Rutgers, The State University of New Jersey
Data source: Rutgers, The State University of New Jersey

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations